Alnylam Pharmaceuticals and GlaxoSmithKline have selected non-profit Bio Ventures for Global Health to oversee the an intellectual property pool that the companies formed last year to assist with the discovery and development of new treatments for neglected tropical diseases.

"By adopting a more accessible approach to intellectual property, the pool facilitates access to compounds and technologies and, most importantly, industrial know-how for organizations that want to conduct research on treatments for these neglected diseases," the companies said.